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Background:  Platelet inhibition by clopidogrel is highly variable and patients with reduced platelet inhibition have increased risk for 
adverse cardiovascular events. Potential mechanisms for this variation include differences in clopidogrel absorption (e.g. due to diet), 
smoking, polymorphisms in CYP2C19 and inhibition of CYP2C19 by proton pump inhibitors (PPIs). Here we report the variability in clopidogrel 
pharmacokinetics (PK) and pharmacodynamics (PD) when the above factors are held constant.
Methods:  Healthy subjects (n=160; age 18-55; homozygous CYP2C19 extensive metabolizer genotype; no nicotine 6 wks, prescription drugs 4 
wks, OTC drugs 2 wks, caffeine and alcohol 72 h, confined, standardized restricted diet) were randomized to a PPI and then to either clopidogrel 
alone or clopidogrel + PPI, washed out, then crossed over to the alternate regimen. Clopidogrel 75 mg with or without a PPI (dexlansoprazole, 
lansoprazole, esomeprazole or omeprazole) was given daily for 9 d. PK was measured on day 9-10 of each period. PD endpoints, measured on days 
7-10, were VASP P2Y12 platelet reactivity index (PRI), maximal platelet aggregation (MPA) to 20 μM ADP, and VerifyNow P2Y12 platelet response 
units (PRU).
Results:  In the absence of PPIs, clopidogrel inhibition of platelet function varied widely between subjects (CVs 36%, 31%, 33% for PRI, MPA, PRU). 
Area under the curve (AUC) for the active metabolite of clopidogrel also varied widely between subjects (CV 35%) and was inversely correlated 
with residual platelet function (r2 = 0.35, 0.31, 0.28 for AUC vs. PRI, MPA, PRU). In contrast, each individual’s level of platelet inhibition remained 
consistent across time (average CVs 16%, 11%, 19% for PRI, MPA, PRU). Similar results were obtained in the presence of each PPI.
Conclusions:  Residual platelet function during clopidogrel therapy varies widely, independent of previously identified factors: CYP2C19 
polymorphisms, diet, nicotine, PPIs and other co-medications. Only 28-35% of this variation was accounted for by the plasma level of the clopidogrel 
active metabolite. Identification of the factors contributing to the residual 65-72% of the variation may have important therapeutic implications.
